Takip et
Mahdi Behdani
Mahdi Behdani
Pasteur Institute of Iran
pasteur.ac.ir üzerinde doğrulanmış e-posta adresine sahip
Başlık
Alıntı yapanlar
Alıntı yapanlar
Yıl
Generation and characterization of a functional Nanobody against the vascular endothelial growth factor receptor-2; angiogenesis cell receptor
M Behdani, S Zeinali, H Khanahmad, M Karimipour, N Asadzadeh, ...
Molecular immunology 50 (1-2), 35-41, 2012
1412012
Development of VEGFR2-specific Nanobody Pseudomonas exotoxin A conjugated to provide efficient inhibition of tumor cell growth
M Behdani, S Zeinali, M Karimipour, H Khanahmad, S Schoonooghe, ...
New biotechnology 30 (2), 205-209, 2013
1152013
Single-domain antibodies or nanobodies: a class of next-generation antibodies
F Khodabakhsh, M Behdani, A Rami, F Kazemi-Lomedasht
International reviews of immunology 37 (6), 316-322, 2018
1092018
Albumin nanoparticles as nanocarriers for drug delivery: Focusing on antibody and nanobody delivery and albumin-based drugs
E Karami, M Behdani, F Kazemi-Lomedasht
Journal of Drug Delivery Science and Technology 55, 101471, 2020
842020
Inhibition of angiogenesis in human endothelial cell using VEGF specific nanobody
F Kazemi-Lomedasht, M Behdani, KP Bagheri, M Habibi-Anbouhi, ...
Molecular immunology 65 (1), 58-67, 2015
842015
Oral DNA vaccines based on CS-TPP nanoparticles and alginate microparticles confer high protection against infectious pancreatic necrosis virus (IPNV) infection in trout
S Ahmadivand, M Soltani, M Behdani, Ø Evensen, E Alirahimi, ...
Developmental & Comparative Immunology 74, 178-189, 2017
712017
An overview on application of phage display technique in immunological studies
A Rami, M Behdani, N Yardehnavi, M Habibi-Anbouhi, ...
Asian Pacific Journal of Tropical Biomedicine 7 (7), 599-602, 2017
682017
T cell engineered with a novel nanobody‐based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy
F Hajari Taheri, M Hassani, Z Sharifzadeh, M Behdani, A Arashkia, ...
IUBMB life 71 (9), 1259-1267, 2019
662019
The first report on transcriptome analysis of the venom gland of Iranian scorpion, Hemiscorpius lepturus
F Kazemi-Lomedasht, V Khalaj, KP Bagheri, M Behdani, ...
Toxicon 125, 123-130, 2017
522017
Rapid and low-cost colorimetric method using 2,3,5-triphenyltetrazolium chloride for detection of multidrug-resistant Mycobacterium tuberculosis
A Mohammadzadeh, P Farnia, K Ghazvini, M Behdani, T Rashed, ...
Journal of medical microbiology 55 (12), 1657-1659, 2006
472006
Preparation and characterization of a novel nanobody against T-cell immunoglobulin and mucin-3 (TIM-3)
V Homayouni, M Ganjalikhani-Hakemi, A Rezaei, H Khanahmad, ...
Iranian Journal of Basic Medical Sciences 19 (11), 1201, 2016
462016
Design and characterization of short hybrid antimicrobial peptides from pEM‐2, mastoparan‐VT 1, and mastoparan‐B
H Memariani, D Shahbazzadeh, R Ranjbar, M Behdani, M Memariani, ...
Chemical Biology & Drug Design 89 (3), 327-338, 2017
452017
Anti-HER2 scFv Expression in Escherichia coli SHuffle®T7 Express Cells: Effects on Solubility and Biological Activity
M Ahmadzadeh, F Farshdari, L Nematollahi, M Behdani, E Mohit
Molecular biotechnology 62 (1), 18-30, 2020
442020
VP2 (PTA motif) encoding DNA vaccine confers protection against lethal challenge with infectious pancreatic necrosis virus (IPNV) in trout
S Ahmadivand, M Soltani, M Behdani, Ø Evensen, E Alirahimi, E Soltani, ...
Molecular immunology 94, 61-67, 2018
442018
Nanobodies as novel therapeutic agents in envenomation
E Alirahimi, F Kazemi-Lomedasht, D Shahbazzadeh, M Habibi-Anbouhi, ...
Biochimica et Biophysica Acta (BBA)-General Subjects 1862 (12), 2955-2965, 2018
422018
A camelid antibody candidate for development of a therapeutic agent against Hemiscorpius lepturus envenomation
N Yardehnavi, M Behdani, KP Bagheri, A Mahmoodzadeh, H Khanahmad, ...
The FASEB Journal 28 (9), 4004, 2014
382014
Design of a humanized anti vascular endothelial growth factor nanobody and evaluation of its in vitro function
F Kazemi-Lomedasht, S Muyldermans, M Habibi-Anbouhi, M Behdani
Iranian journal of basic medical sciences 21 (3), 260, 2018
372018
Development of a mono‐specific anti‐VEGF bivalent nanobody with extended plasma half‐life for treatment of pathologic neovascularization
A Sadeghi, M Behdani, S Muyldermans, M Habibi‐Anbouhi, ...
Drug testing and analysis 12 (1), 92-100, 2020
352020
A nanobody-derived mimotope against VEGF inhibits cancer angiogenesis
E Karami, JM Sabatier, M Behdani, S Irani, F Kazemi-Lomedasht
Journal of enzyme inhibition and medicinal chemistry 35 (1), 1233-1239, 2020
332020
Construction and expression of an anti-VEGFR2 Nanobody-Fc fusionbody in NS0 host cell
M Qasemi, M Behdani, MA Shokrgozar, V Molla-Kazemiha, ...
Protein Expression and Purification 123, 19-25, 2016
322016
Sistem, işlemi şu anda gerçekleştiremiyor. Daha sonra yeniden deneyin.
Makaleler 1–20